Please assess the completion status of the following clinical trial:

Trial Title: BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject provides written informed consent using an Informed Consent Form approved by Ethics Committee/ Institutional Review Board for the site.~2. Subject agrees to comply with the protocol-mandated follow-up procedures and visits.~3. The subject is a male or non-pregnant female ≥ 18 years old with an expected lifespan sufficient to allow for completion of all study procedures.~4. The subject has symptomatic (non-malignant) venous outflow obstruction in iliofemoral venous segments.~5. The subject has symptomatic venous outflow obstruction (non-malignant) in iliofemoral venous segments(Clinical-Etiology-Anatomic-Pathophysiologic (CEAP) C ≥ 3 or VCSS pain score of ≥ 2).~6. The subject is able and willing to comply with any required medication regimen.~7. The reference vessel diameters are between 7mm and 19 mm.~Exclusion Criteria:~1. Subject is unable or unwilling to provide written informed consent, or is unable or unwilling to conform to the study protocol follow-up procedures and visits.~2. Subject is or plans to become pregnant during the study.~3. Subject has contralateral disease of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof and does not meet the venous outflow obstruction requirement or has a malignant obstruction.~4. The subject is asymptomatic, has a CEAP C \<3, or a VCSS pain score of \<2.~5. The subject has a venous obstruction that extends into the inferior vena cava (IVC) or below the level of the lesser trochanter.~6. The subject has a known uncorrectable bleeding diathesis or active coagulopathy.~7. The subject has a known allergy or sensitivity to Nickel or Titanium or intolerance to antiplatelet, anticoagulant or thrombolytic medications medications required per the protocol~8. The subject has a known allergy or sensitivity to contrast media, which cannot be adequately pre-medicated.~9. The subject has any planned surgical interventions within 30 days prior to, or within 30 days after the planned study procedure.~10. The subject has a lesion or occlusion which cannot be traversed with a guidewire.~11. The subject has had prior stenting in the target vessel.~12. The subject has iliofemoral venous segments unsuitable for treatment with available sizes of study devices.~13. The subject has another medical condition, which may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow completion of study procedures and follow ups.~14. The subject is currently participating in an investigational drug, biologic, or another device study.~15. The subject is currently on dialysis or has a serum creatinine ≥2.5mg/dl.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VENOVO™ Venous Stent. (Type: EXPERIMENTAL): Implant of the VENOVO™ Venous Stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete